Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences

Rhea-AI Summary

Simulations Plus, Inc. (Nasdaq: SLP) has entered a distribution agreement with the Institute of Pharmaceutical Sciences (ICF) to enhance marketing and sales support in South America. ICF, a leading pharmaceutical research center, will leverage its expertise and connections to promote Simulations Plus’s products, including GastroPlus® and ADMET Predictor®. This partnership aims to capitalize on the growing $48 billion Latin American generic drug market by advancing model-informed drug development (MIDD) strategies, providing opportunities for research and regulatory interactions.

Positive

• Formed a distribution agreement with ICF, enhancing market presence in South America.
• ICF's established reputation and connections expected to boost product awareness.
• Latin American generic drug market projected to reach $48 billion by 2025, presenting growth opportunities.

Negative

• None.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a distribution agreement with the Institute of Pharmaceutical Sciences (ICF) to provide marketing, sales, and technical support to organizations within South America.

Founded in 2002, ICF is one of the largest pharmaceutical research centers in Latin America and the first commercial Brazilian laboratory to be fully certified by the Brazilian Health Regulatory Agency (ANVISA) to conduct bioavailability and bioequivalence trials. In addition to running clinical trials, ICF has expertise developing complex formulation products such as patches, nasal sprays, and inhalers for organizations globally. With a staff of over 200 highly qualified scientists, ICF will provide extensive connections throughout industry, academia, and regulatory agencies to increase awareness of GastroPlus®, ADMET Predictor®, and related services from Simulations Plus.

“Even though South America has emerged as a global manufacturing hub, with expanded research facilities for pharmaceutical and generic drug companies, the use of model-informed drug development (MIDD) is in its infancy,” said Dr. Leonardo de Souza Teixeira, CEO of ICF. “We are very happy forming this partnership with Simulations Plus to spread the knowledge and application of MIDD to support regulatory interactions.”

“Latin America is one of the fastest growing generic drug markets in the world and expected to reach $48 billion in size by 2025,” added John DiBella, Simulations Plus division president. “To capitalize on this opportunity, especially in the areas of specialty products and non-oral drug delivery systems, we are excited to be partnering with ICF, an established contract research organization (CRO) leader with strong relationships throughout Brazil and neighboring countries. We expect ICF’s expertise administering laboratory testing and clinical studies to complement our offerings to companies throughout the continent and, as a bonus, provide Simulations Plus with new research opportunities to continue advancing modeling and simulation science.”

About Simulations Plus, Inc.
Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, { "@context": "https://schema.org", "@type": "FAQPage", "name": "Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences FAQs", "mainEntity": [ { "@type": "Question", "name": "What is the purpose of the distribution agreement between Simulations Plus and ICF?", "acceptedAnswer": { "@type": "Answer", "text": "The agreement aims to enhance marketing, sales, and technical support for Simulations Plus products in South America." } }, { "@type": "Question", "name": "How will the partnership with ICF benefit Simulations Plus?", "acceptedAnswer": { "@type": "Answer", "text": "ICF's expertise and connections will help promote Simulations Plus products and advance model-informed drug development in the region." } }, { "@type": "Question", "name": "What is the market potential for generics in Latin America?", "acceptedAnswer": { "@type": "Answer", "text": "The Latin American generic drug market is expected to reach $48 billion by 2025." } }, { "@type": "Question", "name": "Which products will ICF promote for Simulations Plus?", "acceptedAnswer": { "@type": "Answer", "text": "ICF will promote Simulations Plus products including GastroPlus® and ADMET Predictor®." } } ] }

FAQ

What is the purpose of the distribution agreement between Simulations Plus and ICF?

The agreement aims to enhance marketing, sales, and technical support for Simulations Plus products in South America.

How will the partnership with ICF benefit Simulations Plus?

ICF's expertise and connections will help promote Simulations Plus products and advance model-informed drug development in the region.

What is the market potential for generics in Latin America?

The Latin American generic drug market is expected to reach $48 billion by 2025.

Which products will ICF promote for Simulations Plus?

ICF will promote Simulations Plus products including GastroPlus® and ADMET Predictor®.